Geneva, 5 June – A team of researchers from the University of Geneva and the CHUV/UNIL collaboration has produced the first detailed three‑dimensional reconstruction of the interaction between cytotoxic T lymphocytes and tumour cells. By applying cryo‑expansion microscopy, the scientists were able to observe the killing apparatus of T cells at nanometre resolution, a development that could inform the next generation of cancer immunotherapies. The method combines rapid cryogenic fixation, which preserves cells in a state that closely resembles their natural environment, with physical expansion of the specimen inside a hydrogel matrix.
This expansion magnifies the structures inside the cells, making them accessible to conventional light microscopes while retaining their spatial relationships. Using this approach, the investigators focused on the immunological synapse – the specialised contact zone where a T cell binds to a target cell.
They discovered that the membrane at this junction adopts a dome‑shaped architecture that cradles the delivery of cytotoxic granules. These granules, which contain proteins such as perforin and granzymes, were seen to vary in the composition of their internal cores. The heterogeneity may help explain why immune attacks sometimes eradicate tumours and at other times fall short.
Importantly, the technique was not limited to cultured cell lines; the researchers successfully applied it to sections of human tumour tissue. This enabled direct visualization of T‑cell activity within the complex micro‑environment of actual cancers, offering a more realistic picture of how immune cells operate in patients.
The findings, published in Cell Reports, represent an early‑stage but promising step toward translating microscopic insight into therapeutic benefit. By mapping the precise geometry and content of the killing machinery, scientists hope to identify why certain tumours resist immune attack and to design strategies that boost the efficacy of existing immunotherapies. Lead investigators highlighted that the ability to study T‑cell behaviour in authentic tumour samples distinguishes this work from earlier studies that relied solely on artificial systems.
“Observing the synapse in its native tissue context provides clues that could be missed in simplified models,” the authors noted. While the research is still in its infancy, the authors anticipate that the high‑resolution view of T‑cell‑cancer interactions will guide the refinement of treatments such as checkpoint inhibitors and CAR‑T cell therapies.
Understanding the structural nuances of the immunological synapse could lead to interventions that enhance granule delivery or stabilize the dome‑like membrane formation, thereby increasing tumour‑cell killing. Patients interested in the implications of this work for their own care are advised to discuss options with their healthcare providers, as the study does not yet translate into clinical protocols.
